

Product Datasheet

Minzasolmin

Catalog No. **BP-01930** · CAS **1802518-92-8** · Form **free base** · Physical state **solid** · Color **Off-white to light yellow** · Version **1.0** · Revision **2026-09-03**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target α-synuclein	Research area Neurological Disease
------------------------------	--

Molecular formula **C₂₃H₃₁N₅OS**

Molecular weight **425.5900**

STRUCTURE



DESCRIPTION

Minzasolmin is an alpha-synuclein oligomerization inhibitor.

BIOLOGICAL ACTIVITY

In Vivo

Minzasolmin (1 mg/kg, 5 mg/kg; intraperitoneal injection; once a day, 5 days a week; 3 months) significantly improves motor coordination ability (such as prolonged rotarod test time), reduces α-synuclein (α-Syn) pathological deposition and neuroinflammatory markers (such as reduced IL-6 levels) in the cerebral cortex and hippocampus, and restores striatal dopamine transporter (DAT) levels in the Thy1-αSyn transgenic mouse model.

SOLUBILITY

Soluble in DMSO 100 mg/mL

REFERENCES

- [1]. Steiner MA. Matters arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease. NPJ Parkinsons Dis. 2024 Mar 14;10(1):59.
- [2]. Baggett, et al. Novel Approaches Targeting in α-Synuclein for Parkinson's Disease: Current Progress and Future Directions for the Disease-Modifying Therapies. Brain Disorders (2024)

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com

BiochemProbe is the catalog brand of Guangzhou Yuyuan Biotech Co., Ltd. · For research use only.

Lot CoA and SDS are separate documents.